LAM
VRTX icon

Lebenthal Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Lebenthal Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-7
Closed -$1K – 685
2016
Q3 		$1K Buy
+7
New +$662 ﹤0.01% 953

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Lebenthal Asset Management's VRTX Position: Q4 2016 in Review

Lebenthal Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2016, closing a stake of 7 shares — an estimated $1K sold.

Lebenthal Asset Management first reported a position in VRTX in Q3 2016 and held it in 1 quarter. The position peaked at $1K in Q3 2016. 483 funds tracked by Wall St. Rank hold VRTX as of Q4 2016.

  • Lebenthal Asset Management reported no remaining Vertex Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Lebenthal Asset Management sold 7 Vertex Pharmaceuticals shares in Q4 2016, an estimated $1K.
  • Lebenthal Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Lebenthal Asset Management's Vertex Pharmaceuticals position peaked at $1K in Q3 2016.
  • 483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2016.

Based on Lebenthal Asset Management's 13F filing for Q4 2016, filed 15 Feb 2017.